MA49510A - Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants - Google Patents
Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondantsInfo
- Publication number
- MA49510A MA49510A MA049510A MA49510A MA49510A MA 49510 A MA49510 A MA 49510A MA 049510 A MA049510 A MA 049510A MA 49510 A MA49510 A MA 49510A MA 49510 A MA49510 A MA 49510A
- Authority
- MA
- Morocco
- Prior art keywords
- isotretinoin
- oral
- related methods
- mucosal formulations
- mucosal
- Prior art date
Links
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title 1
- 229960005280 isotretinoin Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762526743P | 2017-06-29 | 2017-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49510A true MA49510A (fr) | 2020-05-06 |
Family
ID=63036329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049510A MA49510A (fr) | 2017-06-29 | 2018-06-29 | Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants |
Country Status (14)
Country | Link |
---|---|
US (3) | US10874607B2 (fr) |
EP (2) | EP3644961B9 (fr) |
JP (1) | JP2020526579A (fr) |
KR (1) | KR20200135931A (fr) |
CN (1) | CN111032017A (fr) |
AU (1) | AU2018294318A1 (fr) |
CA (1) | CA3068310A1 (fr) |
EA (1) | EA202090164A1 (fr) |
IL (1) | IL271737A (fr) |
MA (1) | MA49510A (fr) |
MX (1) | MX2020000164A (fr) |
PH (1) | PH12020500032A1 (fr) |
SG (1) | SG11201912887VA (fr) |
WO (1) | WO2019006287A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201912887VA (en) | 2017-06-29 | 2020-01-30 | Skyline Biosciences Llc | Isotretinoin oral-mucosal formulations and methods for using same |
DE102019135432A1 (de) * | 2019-12-20 | 2021-06-24 | Lts Lohmann Therapie-Systeme Ag | Lösliche Rückschicht für OTF |
CN113209052B (zh) * | 2021-03-16 | 2022-02-15 | 深圳市泰力生物医药有限公司 | ***二酚自纳米乳口颊膜制剂及其制备方法和用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59232552A (ja) * | 1983-06-16 | 1984-12-27 | 日東電工株式会社 | 粘膜包帯 |
US4678663A (en) * | 1984-02-06 | 1987-07-07 | Nuetrogena Corporation | Hydroquinone composition having enhanced bio-availability and percutaneous adsorption |
JPS63189484A (ja) * | 1987-01-30 | 1988-08-05 | Sekisui Chem Co Ltd | 口腔粘膜貼付剤用の粘着剤組成物 |
US4985235A (en) * | 1988-08-02 | 1991-01-15 | Kligman Albert M | Treatment of periodontoclasia with retinoic acid |
US5188817A (en) * | 1989-03-27 | 1993-02-23 | Julius Ozick | Method of treatment for periodontitis |
US6270781B1 (en) * | 1999-01-08 | 2001-08-07 | Maxim Pharmaceuticals, Inc. | Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors |
KR100403699B1 (ko) * | 2000-03-17 | 2003-11-01 | 주식회사 엘지생활건강 | 치아 미백용 패취 |
PT1318791E (pt) | 2000-09-22 | 2004-11-30 | Galephar M F | Composicao farmaceutica semi-solida de isotretinoina |
JP4850346B2 (ja) * | 2001-03-15 | 2012-01-11 | 救急薬品工業株式会社 | 粘膜貼付剤 |
CN1829490A (zh) * | 2003-07-01 | 2006-09-06 | 托德·迈巴赫 | 包含治疗剂的薄膜 |
JP4413665B2 (ja) * | 2004-03-19 | 2010-02-10 | 救急薬品工業株式会社 | 口腔内粘膜フィルム剤 |
US20050281757A1 (en) * | 2004-06-17 | 2005-12-22 | Sayed Ibrahim | Oral care film |
JP2008526856A (ja) * | 2005-01-05 | 2008-07-24 | ノバセア インコーポレイティッド | 活性ビタミンd化合物またはその模倣体による血栓性疾患の予防 |
WO2006117803A2 (fr) * | 2005-03-14 | 2006-11-09 | Devarajan, Padma, Venkitachalam | Systemes d'administration transmucosale de medicaments |
US9067082B2 (en) * | 2006-07-26 | 2015-06-30 | Ultradent Products, Inc. | Dental bleaching compositions having long-term rheological stability and devices, kits and methods that utilize such compositions |
US20120046354A1 (en) * | 2010-08-18 | 2012-02-23 | Ehrenpreis Eli D | Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders |
US8241661B1 (en) * | 2011-06-24 | 2012-08-14 | Fuisz Richard C | Biocompatible film with variable cross-sectional properties |
US9492426B2 (en) | 2011-09-21 | 2016-11-15 | The Texas A&M University System | Mycophenolic acid analogues as anti-tumor chemosensitizing agents |
US9078925B2 (en) | 2012-06-18 | 2015-07-14 | Galephar Pharmaceutical Research, Inc. | Pharmaceutical semi-solid composition of isotretinoin |
CN103319365B (zh) * | 2013-06-05 | 2015-07-08 | 中国医学科学院皮肤病研究所 | 一种异维甲酸酰胺衍生物及其制备方法和应用 |
RU2016150863A (ru) * | 2014-05-29 | 2018-07-03 | Сан Фармасьютикал Индастриз Лимитед | Пероральная фармацевтическая композиция изотретиноина |
EP3346998A4 (fr) * | 2015-08-17 | 2019-08-28 | Sidmak Laboratories (India) PVT. Ltd. | Système d'administration de film par voie topique |
SG11201912887VA (en) | 2017-06-29 | 2020-01-30 | Skyline Biosciences Llc | Isotretinoin oral-mucosal formulations and methods for using same |
-
2018
- 2018-06-29 SG SG11201912887VA patent/SG11201912887VA/en unknown
- 2018-06-29 JP JP2020521483A patent/JP2020526579A/ja active Pending
- 2018-06-29 EP EP18746354.2A patent/EP3644961B9/fr active Active
- 2018-06-29 MX MX2020000164A patent/MX2020000164A/es unknown
- 2018-06-29 CN CN201880053508.4A patent/CN111032017A/zh active Pending
- 2018-06-29 EA EA202090164A patent/EA202090164A1/ru unknown
- 2018-06-29 MA MA049510A patent/MA49510A/fr unknown
- 2018-06-29 CA CA3068310A patent/CA3068310A1/fr not_active Abandoned
- 2018-06-29 AU AU2018294318A patent/AU2018294318A1/en not_active Abandoned
- 2018-06-29 KR KR1020207002549A patent/KR20200135931A/ko not_active Application Discontinuation
- 2018-06-29 EP EP21188917.5A patent/EP3960155A1/fr not_active Withdrawn
- 2018-06-29 WO PCT/US2018/040267 patent/WO2019006287A1/fr unknown
-
2019
- 2019-11-27 US US16/698,063 patent/US10874607B2/en active Active
- 2019-11-27 US US16/698,062 patent/US10813880B2/en active Active
- 2019-12-26 IL IL271737A patent/IL271737A/en unknown
-
2020
- 2020-01-02 PH PH12020500032A patent/PH12020500032A1/en unknown
- 2020-09-24 US US17/031,334 patent/US20210244656A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200093735A1 (en) | 2020-03-26 |
KR20200135931A (ko) | 2020-12-04 |
CA3068310A1 (fr) | 2019-01-03 |
MX2020000164A (es) | 2020-07-22 |
EA202090164A1 (ru) | 2020-05-14 |
US10813880B2 (en) | 2020-10-27 |
PH12020500032A1 (en) | 2020-09-14 |
US20210244656A1 (en) | 2021-08-12 |
EP3644961A1 (fr) | 2020-05-06 |
AU2018294318A1 (en) | 2020-01-30 |
IL271737A (en) | 2020-02-27 |
EP3960155A1 (fr) | 2022-03-02 |
US10874607B2 (en) | 2020-12-29 |
CN111032017A (zh) | 2020-04-17 |
SG11201912887VA (en) | 2020-01-30 |
JP2020526579A (ja) | 2020-08-31 |
EP3644961B9 (fr) | 2021-10-13 |
EP3644961B1 (fr) | 2021-08-04 |
WO2019006287A1 (fr) | 2019-01-03 |
US20200093734A1 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
MA43802A (fr) | Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA41999A (fr) | Compositions d'acide obéticholique et procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA41951A (fr) | Gènes insecticides et procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA45671A (fr) | Anticorps antivirus zika et procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA55776A (fr) | Gènes pesticides et procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA53235A (fr) | Indoles substitués et procédés d'utilisation associés | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42979A (fr) | Anticorps anti-age et procédés d'utilisation correspondants | |
MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |